Breast Cancer Research and Treatment

, Volume 126, Issue 3, pp 771–778

Mutations in BRCA2 and PALB2 in male breast cancer cases from the United States

  • Yuan Chun Ding
  • Linda Steele
  • Chih-Jen Kuan
  • Scott Greilac
  • Susan L. Neuhausen
Epidemiology

Abstract

Male breast cancer (MBC) is an uncommon disease with a frequency of approximately one in 1000. Due to the rarity of MBC, it is understudied and its etiology is poorly understood. Our objectives are to determine the frequency of pathogenic mutations in BRCA2 and PALB2 in MBC cases and to investigate the correlations between mutation status and cancer phenotypes. Single strand conformation polymorphism analysis, direct sequencing, and multiplex ligation-dependent probe amplification were employed to screen for mutations in the BRCA2 gene, followed by direct sequencing of the PALB2 gene in BRCA2-negative MBC cases. Pathogenic BRCA2 mutations were identified in 18 of the 115 MBC cases, including four of the ten cases (40%) from breast cancer families and 14 of the 105 cases (13%) unselected for family history of breast cancer. The difference in BRCA2-mutation frequencies between cases with and without family history of breast cancer was not statistically significant (P = 0.145), suggesting that family history is not a strong predictor of carrying a mutation in males. We observed a highly significant association of carrying a pathogenic BRCA2 mutation with high tumor grade (P < 0.001) and a weak association with positive lymph nodes (P < 0.02). Of the 97 BRCA2-negative MBC cases, we identified one PALB2 mutation with confirmed pathogenicity and one mutation predicted to be pathogenic, a prevalence of pathogenic PALB2-mutation of 1–2%. Based on our results and previous studies, genetic testing for BRCA2 should be recommended for any diagnosed MBC case, regardless of family history of breast cancer.

Keywords

Male breast cancer BRCA2 PALB2 Genetic testing 

References

  1. 1.
    Hecht JR, Winchester DJ (1994) Male breast cancer. Am J Clin Pathol 102(4 Suppl 1):S25–S30PubMedGoogle Scholar
  2. 2.
    Stratton MR (1996) Recent advances in understanding of genetic susceptibility to breast cancer. Hum Mol Genet 5 Spec No:1515–1519PubMedGoogle Scholar
  3. 3.
    American Cancer Society. Breast Cancer Facts and Figures 2009–2010. Atlanta: American Cancer Society, IncGoogle Scholar
  4. 4.
    Fentiman IS, Fourquet A, Hortobagyi GN (2006) Male breast cancer. Lancet 367(9510):595–604PubMedCrossRefGoogle Scholar
  5. 5.
    Antoniou AC, Easton DF (2006) Models of genetic susceptibility to breast cancer. Oncogene 25(43):5898–5905PubMedCrossRefGoogle Scholar
  6. 6.
    Evans DG, Susnerwala I, Dawson J, Woodward E, Maher ER, Lalloo F (2010) Risk of breast cancer in male BRCA2 carriers. J Med Genet. doi:10.1136/jmg.2009.075176
  7. 7.
    Basham VM, Lipscombe JM, Ward JM, Gayther SA, Ponder BA, Easton DF, Pharoah PD (2002) BRCA1 and BRCA2 mutations in a population-based study of male breast cancer. Breast Cancer Res 4(1):R2PubMedCrossRefGoogle Scholar
  8. 8.
    Besic N, Cernivc B, de Greve J, Lokar K, Krajc M, Novakovic S, Zgajnar J, Teugels E (2008) BRCA2 gene mutations in Slovenian male breast cancer patients. Genet Test 12(2):203–209PubMedCrossRefGoogle Scholar
  9. 9.
    Couch FJ, Farid LM, DeShano ML, Tavtigian SV, Calzone K, Campeau L, Peng Y, Bogden B, Chen Q, Neuhausen S et al (1996) BRCA2 germline mutations in male breast cancer cases and breast cancer families. Nat Genet 13(1):123–125PubMedCrossRefGoogle Scholar
  10. 10.
    Csokay B, Udvarhelyi N, Sulyok Z, Besznyak I, Ramus S, Ponder B, Olah E (1999) High frequency of germ-line BRCA2 mutations among Hungarian male breast cancer patients without family history. Cancer Res 59(5):995–998PubMedGoogle Scholar
  11. 11.
    Diez O, Cortes J, Domenech M, Pericay C, Brunet J, Alonso C, Baiget M (2000) BRCA2 germ-line mutations in Spanish male breast cancer patients. Ann Oncol 11(1):81–84PubMedCrossRefGoogle Scholar
  12. 12.
    Evans DG, Bulman M, Young K, Gokhale D, Lalloo F (2001) High detection rate for BRCA2 mutations in male breast cancer families from North West England. Fam Cancer 1(3–4):131–133PubMedCrossRefGoogle Scholar
  13. 13.
    Friedman LS, Gayther SA, Kurosaki T, Gordon D, Noble B, Casey G, Ponder BA, Anton-Culver H (1997) Mutation analysis of BRCA1 and BRCA2 in a male breast cancer population. Am J Hum Genet 60(2):313–319PubMedGoogle Scholar
  14. 14.
    Haraldsson K, Loman N, Zhang QX, Johannsson O, Olsson H, Borg A (1998) BRCA2 germ-line mutations are frequent in male breast cancer patients without a family history of the disease. Cancer Res 58(7):1367–1371PubMedGoogle Scholar
  15. 15.
    Kwiatkowska E, Teresiak M, Filas V, Karczewska A, Breborowicz D, Mackiewicz A (2003) BRCA2 mutations and androgen receptor expression as independent predictors of outcome of male breast cancer patients. Clin Cancer Res 9(12):4452–4459PubMedGoogle Scholar
  16. 16.
    Mavraki E, Gray IC, Bishop DT, Spurr NK (1997) Germline BRCA2 mutations in men with breast cancer. Br J Cancer 76(11):1428–1431PubMedCrossRefGoogle Scholar
  17. 17.
    Ottini L, Masala G, D’Amico C, Mancini B, Saieva C, Aceto G, Gestri D, Vezzosi V, Falchetti M, De Marco M et al (2003) BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer: a population-based study in Italy. Cancer Res 63(2):342–347PubMedGoogle Scholar
  18. 18.
    Ottini L, Rizzolo P, Zanna I, Falchetti M, Masala G, Ceccarelli K, Vezzosi V, Gulino A, Giannini G, Bianchi S et al (2009) BRCA1/BRCA2 mutation status and clinical-pathologic features of 108 male breast cancer cases from Tuscany: a population-based study in central Italy. Breast Cancer Res Treat 116(3):577–586PubMedCrossRefGoogle Scholar
  19. 19.
    Struewing JP, Coriaty ZM, Ron E, Livoff A, Konichezky M, Cohen P, Resnick MB, Lifzchiz-Mercerl B, Lew S, Iscovich J (1999) Founder BRCA1/2 mutations among male patients with breast cancer in Israel. Am J Hum Genet 65(6):1800–1802PubMedCrossRefGoogle Scholar
  20. 20.
    Syrjakoski K, Kuukasjarvi T, Waltering K, Haraldsson K, Auvinen A, Borg A, Kainu T, Kallioniemi OP, Koivisto PA (2004) BRCA2 mutations in 154 Finnish male breast cancer patients. Neoplasia 6(5):541–545PubMedCrossRefGoogle Scholar
  21. 21.
    Thorlacius S, Sigurdsson S, Bjarnadottir H, Olafsdottir G, Jonasson JG, Tryggvadottir L, Tulinius H, Eyfjord JE (1997) Study of a single BRCA2 mutation with high carrier frequency in a small population. Am J Hum Genet 60(5):1079–1084PubMedGoogle Scholar
  22. 22.
    Wolpert N, Warner E, Seminsky MF, Futreal A, Narod SA (2000) Prevalence of BRCA1 and BRCA2 mutations in male breast cancer patients in Canada. Clin Breast Cancer 1(1):57–63 discussion 64–55PubMedCrossRefGoogle Scholar
  23. 23.
    Xia B, Dorsman JC, Ameziane N, de Vries Y, Rooimans MA, Sheng Q, Pals G, Errami A, Gluckman E, Llera J et al (2007) Fanconi anemia is associated with a defect in the BRCA2 partner PALB2. Nat Genet 39(2):159–161PubMedCrossRefGoogle Scholar
  24. 24.
    Xia B, Sheng Q, Nakanishi K, Ohashi A, Wu J, Christ N, Liu X, Jasin M, Couch FJ, Livingston DM (2006) Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. Mol Cell 22(6):719–729PubMedCrossRefGoogle Scholar
  25. 25.
    Rahman N, Seal S, Thompson D, Kelly P, Renwick A, Elliott A, Reid S, Spanova K, Barfoot R, Chagtai T et al (2007) PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet 39(2):165–167PubMedCrossRefGoogle Scholar
  26. 26.
    Erkko H, Xia B, Nikkila J, Schleutker J, Syrjakoski K, Mannermaa A, Kallioniemi A, Pylkas K, Karppinen SM, Rapakko K et al (2007) A recurrent mutation in PALB2 in Finnish cancer families. Nature 446(7133):316–319PubMedCrossRefGoogle Scholar
  27. 27.
    Foulkes WD, Ghadirian P, Akbari MR, Hamel N, Giroux S, Sabbaghian N, Darnel A, Royer R, Poll A, Fafard E et al (2007) Identification of a novel truncating PALB2 mutation and analysis of its contribution to early-onset breast cancer in French-Canadian women. Breast Cancer Res 9(6):R83PubMedCrossRefGoogle Scholar
  28. 28.
    Garcia MJ, Fernandez V, Osorio A, Barroso A, Llort G, Lazaro C, Blanco I, Caldes T, de la Hoya M, Ramon YCT et al (2009) Analysis of FANCB and FANCN/PALB2 fanconi anemia genes in BRCA1/2-negative Spanish breast cancer families. Breast Cancer Res Treat 113(3):545–551PubMedCrossRefGoogle Scholar
  29. 29.
    Tischkowitz M, Xia B, Sabbaghian N, Reis-Filho JS, Hamel N, Li G, van Beers EH, Li L, Khalil T, Quenneville LA et al (2007) Analysis of PALB2/FANCN-associated breast cancer families. Proc Natl Acad Sci USA 104(16):6788–6793PubMedCrossRefGoogle Scholar
  30. 30.
    Wilson E (1927) Probable inference, the law of succession, and statistical inference. J Am Stat Assoc 22:209–212CrossRefGoogle Scholar
  31. 31.
    Easton DF, Deffenbaugh AM, Pruss D, Frye C, Wenstrup RJ, Allen-Brady K, Tavtigian SV, Monteiro AN, Iversen ES, Couch FJ et al (2007) A systematic genetic assessment of 1, 433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes. Am J Hum Genet 81(5):873–883PubMedCrossRefGoogle Scholar
  32. 32.
    Reid S, Schindler D, Hanenberg H, Barker K, Hanks S, Kalb R, Neveling K, Kelly P, Seal S, Freund M et al (2007) Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer. Nat Genet 39(2):162–164PubMedCrossRefGoogle Scholar
  33. 33.
    Oliver AW, Swift S, Lord CJ, Ashworth A, Pearl LH (2009) Structural basis for recruitment of BRCA2 by PALB2. EMBO Rep 10(9):990–996PubMedCrossRefGoogle Scholar
  34. 34.
    Ramensky V, Bork P, Sunyaev S (2002) Human non-synonymous SNPs: server and survey. Nucleic Acids Res 30(17):3894–3900PubMedCrossRefGoogle Scholar
  35. 35.
    Ferrer-Costa C, Gelpi JL, Zamakola L, Parraga I, de la Cruz X, Orozco M (2005) PMUT: a web-based tool for the annotation of pathological mutations on proteins. Bioinformatics 21(14):3176–3178PubMedCrossRefGoogle Scholar
  36. 36.
    Andrulis IL, Anton-Culver H, Beck J, Bove B, Boyd J, Buys S, Godwin AK, Hopper JL, Li F, Neuhausen SL et al (2002) Comparison of DNA- and RNA-based methods for detection of truncating BRCA1 mutations. Hum Mutat 20(1):65–73PubMedCrossRefGoogle Scholar
  37. 37.
    Jordanova A, Kalaydjieva L, Savov A, Claustres M, Schwarz M, Estivill X, Angelicheva D, Haworth A, Casals T, Kremensky I (1997) SSCP analysis: a blind sensitivity trial. Hum Mutat 10(1):65–70PubMedCrossRefGoogle Scholar
  38. 38.
    Anglian Breast Cancer Study Group (2000) Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Br J Cancer 83(10):1301–1308CrossRefGoogle Scholar
  39. 39.
    Kim SW, Lee CS, Fey JV, Borgen PI, Boyd J (2005) Prevalence of BRCA2 mutations in a hospital based series of unselected breast cancer cases. J Med Genet 42(1):e5PubMedCrossRefGoogle Scholar
  40. 40.
    Sy SM, Huen MS, Zhu Y, Chen J (2009) PALB2 regulates recombinational repair through chromatin association and oligomerization. J Biol Chem 284(27):18302–18310PubMedCrossRefGoogle Scholar
  41. 41.
    Ng PC, Henikoff S (2001) Predicting deleterious amino acid substitutions. Genome Res 11(5):863–874PubMedCrossRefGoogle Scholar
  42. 42.
    Sauty de Chalon A, Teo Z, Park DJ, Odefrey FA, Hopper JL, Southey MC (2010) Are PALB2 mutations associated with increased risk of male breast cancer? Breast Cancer Res Treat 121(1):253–255PubMedCrossRefGoogle Scholar
  43. 43.
    Lord CJ, Ashworth A (2008) Targeted therapy for cancer using PARP inhibitors. Curr Opin Pharmacol 8(4):363–369PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2010

Authors and Affiliations

  • Yuan Chun Ding
    • 1
  • Linda Steele
    • 1
  • Chih-Jen Kuan
    • 2
  • Scott Greilac
    • 3
  • Susan L. Neuhausen
    • 1
  1. 1.Department of Population SciencesBeckman Research of Institute at the City of HopeDuarteUSA
  2. 2.Formerly at University of California IrvineIrvineUSA
  3. 3.PrimeGen Biotech LLCIrvineUSA

Personalised recommendations